The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Looks like members of the AACR attend this annual conference.
Members include laboratory, translational, and clinical researchers; other health care professionals; and cancer advocates. Membership includes 289 Fellows of the AACR Academy; 56 are Nobel laureates.
No doubt large pharmas have a few researchers amongst their personnel.
Onwards Avacta.
Cheers, Timster.
Since last time I checked, Manchester and Glasgow have started recruitment.
https://clinicaltrials.gov/ct2/show/NCT04969835#contactlocation
Onwards Avacta.
I reckon Dr Goldberg played a part in obtaining our slot:
https://www.yorkshirepost.co.uk/business/avacta-announces-appointment-of-new-non-executive-director-3350226
Onwards Avacta.
Gadgie,
Not sure that "Simply Wall Street", based in Australia, has got this right as the %ages quoted would have required TR1s and I can't find any for them. Neither do they appear on the Avacta website.
Am I missing something?
... are closing their short, then they need to buy the shares back.
They can only do this if people are prepared to sell. If people hold then they will need to pay a higher price.
Who knows what they might have to pay if there was a surge in buys.
I agree we might see some shenanigans but the principle remains.
They certainly won't want a positive RNS on any topic.
Onwards Avacta.
Whilst I am by no means an expert, my understanding is that to short a share you borrow shares to sell and then try and buy them back at less than you sold them for in order to make a profit.
The risk is that as you buy the shares back the price goes up beyond the price that you sold at and this is the risk being taken by any shorter.
Holding and buying by existing holders is the best way to increase that risk for the shorter.
Happy to be corrected but sticking with that approach to await the sp increase when shorters have to buy back
Onwards Avacta.
uamalik,
You told us that you sold up at 73p and were waiting for a lower reentry point. Looks like that hasn't changed.
When you say that there are no inflection points for five months, does that mean that Daewong, LG Chem, Point, Moderna and others have all told you that nothing is happening?
Please clarify. Thanks.